RxDoctor Payments Data

William Carley, MD

Family Medicine · San Diego, CANPI 1063432631

Payments from drug & device makers

$5,012in general payments, 2019–2025

Across 261 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$909
  • Pfizer$710
  • GSK$298
  • Merck$235
  • Lilly USA, LLC$221
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$5,012100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,012 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$188,121
Medicare patients
530
Services billed
2,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$56,693
JardianceEmpagliflozin28$32,472
EliquisApixaban35$28,673
RybelsusSemaglutide16$26,601
SynthroidLevothyroxine Sodium150$15,645
JanuviaSitagliptin Phosphate15$13,888
PremarinEstrogens, Conjugated12$6,646
TrintellixVortioxetine Hydrobromide12$5,600
Atorvastatin Calcium537$5,313
Icosapent Ethyl20$5,287
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$3,207
Rosuvastatin Calcium205$2,654
Celecoxib74$2,230
Raloxifene Hcl32$1,985
Levothyroxine Sodium156$1,829

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$909$83,29572 claims
PfizerEliquis, Premarin$710$35,31947 claims
Boehringer IngelheimJardiance$59$32,47228 claims
AbbVieSynthroid$1,435$15,645150 claims
MerckJanuvia$235$13,88815 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$68$5,60012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →